Active Ingredient History
Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants at high-risk for RSV due to conditions such as prematurity or other medical problems including heart or lung diseases. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Bronchopulmonary Dysplasia (Phase 2/Phase 3)
Healthy Volunteers (Phase 1)
Heart Defects, Congenital (Phase 2/Phase 3)
Infant, Premature (Phase 2)
Infant, Premature, Diseases (Phase 2)
Lung Diseases (Phase 4)
Neoplasms (Phase 3)
Premature Birth (Phase 2/Phase 3)
Respiratory Syncytial Virus Infections (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
